ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Avidity Biosciences, Inc. Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.	United States of America	RNA
Axsome Therapeutics, Inc. Biopharma company developing novel therapies for central nervous system (CNS) conditions.	United States of America	AXSM
AYTU BIOPHARMA, INC Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.	United States of America	AYTU
Azitra, Inc. Developing engineered proteins and live biotherapeutics for rare skin diseases.	United States of America	AZTR
Bachem Holding AG A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.	Switzerland	BANB
Barinthus Biotherapeutics plc. Develops T cell immunotherapies for autoimmune and chronic infectious diseases.	United States of America	BRNS
Basilea Pharmaceutica AG Develops & commercializes anti-infectives for severe bacterial & fungal infections.	Switzerland	BSLN
Bausch Health Companies Inc. Develops, manufactures, and markets pharmaceuticals, OTCs, and medical devices globally.	United States of America	BHC
Bavarian Nordic A biotech firm developing and manufacturing life-saving vaccines for travel and public health.	Denmark	BAVA
Bayer AG A life science firm providing pharmaceuticals, consumer health, and crop science solutions.	Germany	BAY